Co-Diagnostics Earnings Surge Cant Stop the Slide

Co-diagnostics (NASDAQ: CODX) reported its fiscal 2025 Q4 earnings on March 31, 2026, revealing a significant increase in revenue but a deepening net loss. The company’s performance fell short of profitability, and no material guidance adjustments were made for the current year.

Revenue

Co-diagnostics saw a substantial 76.7% year-over-year increase in total revenue, reaching $263,922 in the fourth quarter of 2025 compared to $149,325 in the same period of 2024. This growth highlights the company’s ability to scale operations and generate higher top-line results despite ongoing financial challenges.

Earnings/Net Income

Despite the revenue gain, the company’s losses expanded, with a per-share loss of $0.42 in 2025 Q4—26.7% wider than the $0.33 per share loss in 2024. Overall, the net loss grew to $25.75 million, up 133.4% from $11.03 million in the prior-year period. The widening losses reflect ongoing investment in operations and expansion, which currently outweigh revenue gains. This indicates a continued financial challenge for the company.

Price Action

The stock price of Co-diagnostics has shown mixed performance in recent trading periods, with an 8.14% jump during the latest trading day, but a 18.06% decline over the most recent full trading week and a steep 66.55% drop month-to-date. These movements reflect market uncertainty and volatility surrounding the company’s financial performance and future prospects.

Post Earnings Price Action Review

A historical strategy of purchasing Co-diagnostics shares after a revenue decline in its quarterly report has yielded poor results over the past three years, with a return of -45.67% compared to -5.16% for the benchmark. The strategy exhibited a maximum drawdown of 54.40% and a Sharpe ratio of -0.26, both of which signal high risk and poor performance. This underscores the challenges investors face when attempting to time the market around the company's earnings releases.

CEO Commentary

Dwight Egan, CEO, outlined a multi-faceted growth strategy centered on advancing clinical pipelines for upper respiratory, TB, and HPV tests. The company is also scaling its CoSara and CoMira platforms in India and Saudi Arabia, respectively, with the aim of achieving local production and regulatory compliance. Egan emphasized the importance of AI in enhancing diagnostic capabilities and highlighted key milestones, including CoSara's CDSCO manufacturing license and CoMira’s alignment with Saudi healthcare goals. Despite current financial headwinds, Egan expressed optimism about long-term commercial adoption and shareholder value creation.

Guidance

Looking ahead to 2026, the company aims to commercialize its TB test in India by Q3 and submit its upper respiratory panel for clinical approval. Egan also noted the flexibility to reintroduce the COVID target in its multiplex test, subject to FDA consultation. CoMira’s technology transfer and manufacturing readiness in India are prioritized, with timelines contingent on clinical trial execution. The company remains focused on disciplined capital allocation, regulatory progress, and AI integration to drive long-term success.

Additional News

In early April 2026, Co-diagnostics announced plans to explore a potential SPAC transaction for its CoSara division, aiming to accelerate commercialization and access new capital. The company also disclosed that its Chief Strategy Officer, Priya Kaul, will assume additional responsibilities in business development, reflecting a strategic realignment to boost global expansion efforts. Additionally, Co-diagnostics announced a share repurchase program, signaling confidence in its long-term value proposition despite ongoing financial challenges.